Loading
Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.
Sara López-Tarruella is a medical oncologist at Hospital General Universitario Gregorio Marañón in Madrid. Her specialisms are breast cancer, triple-negative disease and neoadjuvant trials, and she leads GEICAM neoadjuvant studies of chemotherapy and immunotherapy in triple-negative and HER2-positive breast cancer. Her papers include a Future Oncology piece on how to treat HR-positive, HER2-negative early breast cancer, a study of docetaxel, carboplatin and doxorubicin activity in patient-derived triple-negative xenografts, and an Annals of Oncology report on the TNBC-DX genomic test in early triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Her publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| How we Treat HR-Positive, HER2-Negative Early Breast Cancer | Future Oncology | 2022 |
| Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts | Scientific Reports | 2021 |
| TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy | Annals of Oncology | 2025 |
Shares Hospital General Universitario Gregorio Marañón, GEICAM Spanish Breast Cancer Group, Triple-negative breast cancer (TNBC).
Shares GEICAM Spanish Breast Cancer Group, Triple-negative breast cancer (TNBC).
Shares GEICAM Spanish Breast Cancer Group, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
Shares GEICAM Spanish Breast Cancer Group, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).